article thumbnail

RNA processing in health and disease: challenges and opportunities of the field

Drug Target Review

Hasson’s interest in drug discovery began early in his training, where he was able to work on chemical biology and microplate-based high throughput assays as a graduate student. After completing his postdoc, Sam undertook an industrial career in drug discovery, with an emphasis on neurodegenerative diseases, at Pfizer and then Amgen.

RNA 96
article thumbnail

New image-based cellular profiling tool peers deeply into metabolic biology

Broad Institute

Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize. Fat cells stained yellow to show the actin cytoskeleton, plasma membrane, and Golgi apparatus. Credit: Phil Kubitz, Claussnitzer lab Fat cells stained blue to show nuclei. “I

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advancements in hit identification for membrane protein drug discovery

Drug Target Review

The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions.

article thumbnail

Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment

Sygnature Discovery

The biotech will continue partnering with Sygnature to drive its novel, genetically validated cardiovascular disease project pipeline. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases and more.

article thumbnail

Roche signs definitive share purchase agreement with long-term partner TIB.

The Pharma Data

TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche`s LightCycler PCR instruments.

Virus 52
article thumbnail

OTAT Town Hall on Cell Therapy CMC – The Recording is Available but Here’s an Appetizer

FDA Law Blog: Drug Discovery

The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. The next town hall will focus on the clinical development of gene therapy products for rare diseases in February 2023.

article thumbnail

Brochure: Dynabeads manual and automated SARS-CoV-2 enrichment

The Pharma Data

Accurate and timely laboratory diagnosis of COVID-19 is one of the most pivotal requirements for optimal disease management and contact tracing. A schematic of domain and functional organization of two of the major structural proteins of SARS-CoV-2, Nucleocapsid protein as a target viral antigen for assay development.

Virus 52